Ranolazine triggers pharmacological preconditioning and postconditioning in anesthetized rabbits through activation of RISK pathway

European Journal of Pharmacology

Volumn 789, Issue , 2016, Pages 431-438

  Efentakis, Panagiotis ^a   Andreadou, Ioanna ^a   Bibli, Sophia Iris ^a   Vasileiou, Styliani ^a   Dagres, Nikolaos ^b   Zoga, Anastasia ^b   Lougiakis, Nikolaos ^a   Kremastinos, Dimitrios Th ^b   Iliodromitis, Efstathios K ^b  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Cardioprotection; Postconditioning; Preconditioning; Ranolazine; RISK pathway

Indexed keywords

ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLYCOGEN SYNTHASE KINASE 3BETA; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN KINASE B; RANOLAZINE; WORTMANNIN; CARDIOTONIC AGENT; PHOSPHATIDYLINOSITOL 3 KINASE;

ANESTHESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; HEART HEMODYNAMICS; HEART INFARCTION; HEART INFARCTION SIZE; HEART PROTECTION; IMMUNOBLOTTING; INTRACELLULAR SIGNALING; MALE; NONHUMAN; PRIORITY JOURNAL; RABBIT; REPERFUSION INJURY; RISK ASSESSMENT; ANIMAL; DRUG EFFECTS; HEART INFARCTION PREVENTION; HEMODYNAMICS; ISCHEMIC POSTCONDITIONING; METABOLISM; MYOCARDIAL ISCHEMIA REPERFUSION INJURY; PATHOLOGY; PATHOPHYSIOLOGY; PHOSPHORYLATION; PROCEDURES; SIGNAL TRANSDUCTION;

ANESTHESIA; ANIMALS; CARDIOTONIC AGENTS; GLYCOGEN SYNTHASE KINASE 3 BETA; HEMODYNAMICS; ISCHEMIC POSTCONDITIONING; ISCHEMIC PRECONDITIONING, MYOCARDIAL; MALE; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MYOCARDIAL REPERFUSION INJURY; NITRIC OXIDE SYNTHASE TYPE III; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RABBITS; RANOLAZINE;

EID: 84981288068     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2016.08.001     Document Type: Article

References (32)

1. Aldakkak, M., Camara, A.K.S., Heisner, J.S., Yang, M., Stowe, D.F., Ranolazine reduces Ca2+overload and oxidative stress and improves mitochondrial integrity to protect against ischemia reperfusion injury in isolated hearts. Pharmacol. Res. 64 (2011), 381–392.
2. Allely, M.C., Alps, B.J., Prevention of myocardial enzyme release by ranolazine in a primate model of ischaemia with reperfusion. Br. J. Pharmacol. 99 (1990), 5–6.
3. Andreadou, I., Bibli, S.I., Mastromanolis, E., Zoga, A., Efentakis, P., Papaioannou, N., Farmakis, D., Kremastinos, D.T., Iliodromitis, E.K., Transient carotid ischemia as a remote conditioning stimulus for myocardial protection in anesthetized rabbits: insights into intracellular signaling. Int. J. Cardiol. 184 (2015), 140–151.
4. Andreadou, I., Farmakis, D., Prokovas, E., Sigala, F., Zoga, A., Spyridaki, K., Papalois, A., Papapetropoulos, A., Anastasiou-Nana, M., Kremastinos, D.T., Iliodromitis, E.K., Short-term statin administration in hypercholesterolaemic rabbits resistant to postconditioning: effects on infarct size, endothelial nitric oxide synthase, and nitro-oxidative stress. Cardiovasc. Res. 94 (2012), 501–509.
5. Belardinelli, L., Shryock, J.C., Fraser, H., Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine. Heart, 92(Suppl 4), 2006 iv6-iv14.
6. Bell, R.M., Yellon, D.M., Atorvastatin, administered at the onset of reperfusion, and independent of lipid lowering, protects the myocardium by up-regulating a pro-survival pathway. J. Am. Coll. Cardiol. 41 (2003), 508–515.
7. Bibli, S.I., Andreadou, I., Chatzianastasiou, A., Tzimas, C., Sanoudou, D., Kranias, E., Brouckaert, P., Coletta, C., Szabo, C., Kremastinos, D.T., Iliodromitis, E.K., Papapetropoulos, A., Cardioprotection by H2S engages a cGMP-dependent protein kinase G/phospholamban pathway. Cardiovasc. Res. 106 (2015), 432–442.
8. Chaitman, B.R., Pepine, C.J., Parker, J.O., Skopal, J., Chumakova, G., Kuch, J., Wang, W., Skettino, S.L., Wolff, A.A., Combination Assessment of Ranolazine In Stable Angina, I., Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. J. Am. Med. Assoc. 291 (2004), 309–316.
9. Chaitman, B.R., Skettino, S.L., Parker, J.O., Hanley, P., Meluzin, J., Kuch, J., Pepine, C.J., Wang, W., Nelson, J.J., Hebert, D.A., Wolff, A.A., Investigators, M., Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. J. Am. Coll. Cardiol. 43 (2004), 1375–1382.
10. Clarke, B., Spedding, M., Patmore, L., McCormack, J.G., Protective effects of ranolazine in guinea-pig hearts during low-flow ischaemia and their association with increases in active pyruvate dehydrogenase. Br. J. Pharmacol. 109 (1993), 748–750.
11. Clarke, B., Wyatt, K.M., McCormack, J.G., Ranolazine increases active pyruvate dehydrogenase in perfused normoxic rat hearts: evidence for an indirect mechanism. J. Mol. Cell. Cardiol. 28 (1996), 341–350.
12. Fath-Ordoubadi, F., Beatt, K.J., Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: an overview of randomized placebo-controlled trials. Circulation 96 (1997), 1152–1156.
13. Fredj, S., Sampson, K.J., Liu, H., Kass, R.S., Molecular basis of ranolazine block of LQT-3 mutant sodium channels: evidence for site of action. Br. J. Pharmacol. 148 (2006), 16–24.
14. Hale, S.L., Kloner, R.A., The antianginal agent, ranolazine, reduces myocardial infarct size but does not alter anatomic no-reflow or regional myocardial blood flow in ischemia/reperfusion in the rabbit. J. Cardiovasc. Pharmacol. Ther. 13 (2008), 226–232.
15. Hale, S.L., Leeka, J.A., Kloner, R.A., Improved left ventricular function and reduced necrosis after myocardial ischemia/reperfusion in rabbits treated with ranolazine, an inhibitor of the late sodium channel. J. Pharmacol. Exp. Ther. 318 (2006), 418–423.
16. Hale, S.L., Shryock, J.C., Belardinelli, L., Sweeney, M., Kloner, R.A., Late sodium current inhibition as a new cardioprotective approach. J. Mol. Cell. Cardiol. 44 (2008), 954–967.
17. Hausenloy, D.J., Yellon, D.M., Ischaemic conditioning and reperfusion injury. Nat. Rev. Cardiol., 2016.
18. Heusch, G., Reduction of infarct size by ischaemic post-conditioning in humans: fact or fiction?. Eur. Heart J. 33 (2012), 13–15.
19. Heusch, G., Molecular basis of cardioprotection: signal transduction in ischemic pre-, post-, and remote conditioning. Circ. Res. 116 (2015), 674–699.
20. Iliodromitis, E.K., Andreadou, I., Iliodromitis, K., Dagres, N., Ischemic and postischemic conditioning of the myocardium in clinical practice: challenges, expectations and obstacles. Cardiology 129 (2014), 117–125.
21. Iliodromitis, E.K., Cohen, M.V., Dagres, N., Andreadou, I., Kremastinos, D.T., Downey, J.M., What is wrong with cardiac conditioning? We may be shooting at moving targets. J. Cardiovasc. Pharmacol. Ther. 20 (2015), 357–369.
22. McCormack, J.G., Barr, R.L., Wolff, A.A., Lopaschuk, G.D., Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts. Circulation 93 (1996), 135–142.
23. Mehta, S.R., Yusuf, S., Diaz, R., Zhu, J., Pais, P., Xavier, D., Paolasso, E., Ahmed, R., Xie, C., Kazmi, K., Tai, J., Orlandini, A., Pogue, J., Liu, L., Investigators, C.-E.T.G., Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. J. Am. Med. Assoc. 293 (2005), 437–446.
24. Morrow, D.A., Scirica, B.M., Karwatowska-Prokopczuk, E., Murphy, S.A., Budaj, A., Varshavsky, S., Wolff, A.A., Skene, A., McCabe, C.H., Braunwald, E., Investigators, M.-T.T., Effects of ranolazine on recurrent cardiovascular events in patients with non-ST-elevation acute coronary syndromes: the MERLIN-TIMI 36 randomized trial. J. Am. Med. Assoc. 297 (2007), 1775–1783.
25. Mourouzis, I., Mantzouratou, P., Galanopoulos, G., Kostakou, E., Dhalla, A.K., Belardinelli, L., Pantos, C., The beneficial effects of ranolazine on cardiac function after myocardial infarction are greater in diabetic than in nondiabetic rats. J. Cardiovasc. Pharmacol. Ther. 19 (2014), 457–469.
26. Nikolaidis, L.A., Mankad, S., Sokos, G.G., Miske, G., Shah, A., Elahi, D., Shannon, R.P., Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 109 (2004), 962–965.
27. Ovize, M., Thibault, H., Przyklenk, K., Myocardial conditioning: opportunities for clinical translation. Circ. Res. 113 (2013), 439–450.
28. Takahashi, K., Takahashi, T., Suzuki, T., Onishi, M., Tanaka, Y., Hamano-Takahashi, A., Ota, T., Kameo, K., Matsuda, T., Baba, A., Protective effects of SEA0400, a novel and selective inhibitor of the Na+/Ca2+ exchanger, on myocardial ischemia-reperfusion injuries. Eur. J. Pharmacol. 458 (2003), 155–162.
29. Undrovinas, A.I., Belardinelli, L., Undrovinas, N.A., Sabbah, H.N., Ranolazine improves abnormal repolarization and contraction in left ventricular myocytes of dogs with heart failure by inhibiting late sodium current. J. Cardiovasc. Electro. 17:Suppl 1 (2006), S169–S177.
30. Yang, X.M., Liu, Y., Cui, L., Yang, X., Liu, Y., Tandon, N., Kambayashi, J., Downey, J.M., Cohen, M.V., Two classes of anti-platelet drugs reduce anatomical infarct size in monkey hearts. Cardiovasc. Drugs Ther. 27 (2013), 109–115.
31. Yao, Z., Gong, S., Guan, T., Li, Y., Wu, X., Sun, H., Synthesis of ranolazine metabolites and their anti-myocardial ischemia activities. Chem. Pharmacol. Bull. 57 (2009), 1218–1222.
32. Zacharowski, K., Blackburn, B., Thiemermann, C., Ranolazine, a partial fatty acid oxidation inhibitor, reduces myocardial infarct size and cardiac troponin T release in the rat. Eur. J. Pharmacol. 418 (2001), 105–110.